Prospective observational study on cytokine removal effect of continuous hemodiafiltration in COVID-19

Prospective observational study on cytokine removal effect of continuous hemodiafiltration in COVID-19 - Prospective observational study on cytokine removal effect of continuous hemodiafiltration in COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040563

Enrollment

Registered

2020-05-28

Start date

2020-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with COVID-19 and undergoing continuous hemodiafiltration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with written or verbal consent

Exclusion criteria

Exclusion criteria: Patients who the investigator determined to be inappropriate as subjects (Patients with severe anemia of Hb <6.0 g/dL, those with systolic blood pressure <70mmHg even after using sufficient amount of vasopressor)

Design outcomes

Primary

Measure	Time frame
Changes in various blood cytokine levels 2, 18 and 24 hours after the start of CHDF and the outcome 30 days later	—

Countries

Japan

Contacts

Public ContactJunichiro Nakata

Juntendo University Hospital Department of Nephrology

jnakata@juntendo.ac.jp03-3813-3111

Outcome results